Companies / Santa Cruz Biotechnology / CD28 (37.51.1)
Santa Cruz Biotechnology

CD28 (37.51.1) | Santa Cruz Biotechnology

(0) Write Review

hamster monoclonal IgG; T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2), expressed on antigen presenting cells, bind the homologous T cell receptors CD28 and CTLA-4 (cytotoxic T lymphocyte-associated protein-4). The dominant co-stimulatory receptor CD28 is expressed on resting T-cells, while CTLA-4 is expressed as a co-inhibitory receptor on activated T-cells, and binds CD80 and CD86 with higher affinity then CD28. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counterreceptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.

Learn More

Reviews

(0) | Be the first to review this product
No reviews yet

ABOUT THE COMPANY

Santa Cruz Biotechnology

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research antibodies, siRNA and CRISPR Gene editing tools, biochemicals, labware and more recently has expanded into animal health care products. Santa Cruz Biotechnology has the highest commitment to quality and customer service.

Scientific Products
  • See More
    • Upcoming Virtual Events
    Upcoming Webinars